Drugs / 8-Chloroadenosine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05263284 | Dec 2022 → Jan 2029 expected | acute myeloid leukemia | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT00714103 | Jun 2008 → Oct 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02509546 | Sep 2015 → Mar 2021 | acute myeloid leukemia | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 8-chloro-adenosine | “The goal of this clinical research study is to find the highest safe dose of the drug 8-chloro-adenosine that can be given in the treatment of chronic lymphocytic leukemia (CLL).” NCT00714103 ↗ |
| Known as | NSC-354258 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594396 ↗ |
| Modality | Small molecule | “8-Chloro-adenosine belongs to a class of chemotherapy drugs called purine analogues” NCT00714103 ↗ |
| Route | Intravenous | “intravenous over 1 hour” NCT00714103 ↗ |